Brazil Resumes Testing Chinese COVID-19 Vaccine Candidate

Sao Paulo-based National Health Surveillance Agency (Anvisa) has authorized the resumption of a phase III clinical trial of the CoronaVac vaccine candidate in Brazil, according to a press statement issued by Sinovac Biotech Ltd. on November 11, 2020.

'We have learned that Anvisa failed to receive the data sent by Butantan Institute in time, and it urgently suspended the clinical study on November 9. Butantan Institute communicated with Anvisa on November 10, and the report from the Data and Safety Monitoring Board (DSMB) was submitted to Anvisa on the same day.'

'After evaluating the new DSMB data, Anvisa made a very timely decision to resume the clinical research of the coronavirus preventive CoronaVac vaccine.